Tae Fukushima

This inventor holds 8 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignee: Otsuka Pharmaceutical Company, Limited. Active years: 2010-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tae Fukushima. Retrieved from https://idiyas.com/inventor/tae-fukushima

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 4)

% Patents Active = 12.5

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 14.9

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

Tokushima, JP (2010 - 2013)
Osaka, JP (2013 - 2020)

Company Filing History:

8 out of 846

Otsuka Pharmaceutical Company, Limited

patents

Years Active: 2010-2020

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10626095 - Cyanotriazole compounds (2020-04-21),

2. 9630947 - Therapeutic compounds and related methods of use (2017-04-25),

3. 9073890 - Therapeutic compounds and related methods of use (2015-07-07),

4. 8551999 - Heterocyclic compound and pharmaceutical composition thereof (2013-10-08),

5. 8362252 - Carbostyril compound (2013-01-29),

6. 8188277 - Aromatic compounds for suppressing the generation of collagen (2012-05-29),

7. 8071600 - Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders (2011-12-06),

8. 7777038 - Carbostyril compound (2010-08-17),

Title: The Innovative Contributions of Tae Fukushima

Introduction

Tae Fukushima is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 8 patents. His work focuses on developing compounds that have therapeutic applications, particularly in treating metabolic and cognitive disorders.

Latest Patents

Fukushima's latest patents include innovative compounds such as cyanotriazole compounds. These compounds are designed to stimulate citric acid cycle activity and improve hyperglycemia with minimal side effects. They are particularly useful in treating conditions like diabetes, insulin resistance, and cardiovascular diseases. Another notable patent involves therapeutic compounds that modulate striatal-enriched tyrosine phosphatase (STEP), which are aimed at treating disorders such as schizophrenia and cognitive deficits.

Career Highlights

Tae Fukushima is currently employed at Otsuka Pharmaceutical Company, Limited, where he continues to advance his research and development efforts. His work has garnered attention for its potential to improve the quality of life for individuals suffering from various health conditions.

Collaborations

Fukushima collaborates with talented colleagues, including Takeshi Kuroda and Takumi Sumida, who contribute to his innovative projects and research initiatives.

Conclusion

Tae Fukushima's contributions to the field of pharmaceuticals through his patents and research are noteworthy. His innovative compounds hold promise for treating significant health issues, showcasing the impact of his work in the medical community.

Profile summary based on public USPTO records.